Skinvisible, Inc. (SKVI)
Oxford Ledge is still expanding full research coverage of SKVI. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Skinvisible licenses patented polymer delivery technology and formulated skincare products to pharmaceutical and consumer goods companies worldwide.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-13
- 10-K Annual financial report with audited statements 2026-03-31
- 10-Q Quarterly financial report (unaudited) 2025-11-13
- 10-Q Quarterly financial report (unaudited) 2025-08-13
- 10-Q Quarterly financial report (unaudited) 2025-05-14
Source: SEC EDGAR.
Annual results
5 years of annual figures for SKVI, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $20,000 | -$1.1M | — |
| 2024 | $20,000 | -$565,654 | -$0.11 |
| 2023 | $20,000 | -$2.4M | -$0.52 |
| 2022 | $279,296 | -$1.2M | -$0.27 |
| 2021 | $663,426 | -$1.1M | -$0.24 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for SKVI. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open SKVI in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.